The 2021 ESMO Congress took place virtually Sept 16-21 and included important practice-changing research. 

MD /alert compiled a list of the top 5 stories you can’t miss. 

Relapse More Common After Best Supportive Care in IMpower010 Study

Patients enrolled in the IMpower010 clinical trial assigned to best supportive care experienced higher rates of relapse than those assigned to adjuvant cancer immunotherapy for non–small cell lung cancer. READ MORE.

Combined Durvalumab Consolidation Therapy Improves Outcomes in Patients With Unresectable Locally Advanced NSCLC

The addition of oleclumab or monalizumab to durvalumab consolidation therapy improved outcomes in comparison to durvalumab monotherapy in patients with unresectable, locally advanced non–small cell lung cancer. READ MORE.

Chemotherapy-Free Regimen Shows Promise for Patients With Advanced NSCLC

AK104, an investigational bispecific antibody, exhibited promising antitumor activity when given in combination with the tyrosine kinase inhibitor anlotinib to treatment-naive patients with advanced non–small cell lung cancer. READ MORE.

Oral TKI Doublet a Promising Option for Patients With NSCLC, EGFR Mutations

An all-oral doublet composed of anlotinib and gefitinib exhibited efficacy in patients with treatment-naive, EGFR–mutated advanced non–small cell lung cancer. READ MORE.

KRAS Mutations Predict Immunotherapy Benefit for Patients With Advanced NSCLC 

Patients with advanced non–small cell lung cancer harboring KRAS mutations experienced longer survival intervals when treated with immune checkpoint inhibitors as monotherapy. READ MORE.